PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsendometrial neoplasms
MeSH D016889 - endometrial neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D014594:Uterine neoplasms
27 Companies
4 Drugs
$
Success rate
D016889: 
Endometrial neoplasms
54 Companies
10 Drugs
$
Success rate
D018269:Endometrioid carcinoma
0 Companies
0 Drugs
Success rate
D036821:Endometrial stromal tumors
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCarboplatin Carboplatin  2005-09-21   
Medroxyprogesterone Medroxyprogesterone  2004-10-27   
Megestrol Megestrol  1998-02-27   
Cyclophosphamide Neosar  1993-04-29   
Novast LaboratoriesCarboplatin Carboplatin  2017-04-26   
Dr Reddys LaboratoriesCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
MylanCarboplatin Carboplatin  2007-04-24   
NATCO PharmaCarboplatin Carboplatin  2012-05-29   
XiromedMedroxyprogesterone Medroxyprogesterone  2018-10-12   
Johnson & JohnsonLeuprolide Viadur  2000-03-03   
GSKDostarlimab Jemperli  2021-04-21   
CiplaCarboplatin Carboplatin  2006-01-27   
Cyclophosphamide Cyclophosphamide  2019-01-18   
Medroxyprogesterone Medroxyprogesterone  2019-01-25   
SandozCarboplatin Carboplatin  2005-03-18   
Leuprolide Leuprolide  1998-08-04   
Medroxyprogesterone Medroxyprogesterone  2009-05-20   
Cyclophosphamide Cyclophosphamide  2023-09-12   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
71%
77/108
Phase 2
24%
36/151
Phase 3
26%
14/53
Approved: 7Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Carboplatin,
Cyclophosphamide,
Medroxyprogesterone,
Medroxyprogesterone acetate
Mylan
Carboplatin
Johnson & Johnson
Leuprolide
GSK
Dostarlimab,
Transplatin,
Antithrombin iii,
Bevifimod,
Arm1,
Arm2,
Evidence
Sandoz
Carboplatin
AbbVie
Leuprolide,
Norethindrone,
Budigalimab
Sanofi
Leuprolide,
Transplatin,
PILARALISIB,
SERIBANTUMAB,
Docetaxol
Merck & Co
Pembrolizumab,
Sacituzumab,
Transplatin,
Chlormadinone acetate,
Albumin,
Epacadostat,
Aglatimagene besadenovec,
Patritumab,
Ridaforolimus,
Patritumab deruxtecan,
Bevifimod,
Favezelimab,
SECLIDEMSTAT,
Telbermin,
Vibostolimab,
Vilobelimab,
Zoptarelin doxorubicin,
Mk-4280,
Caelyx,
Nerofe,
Doxorubin,
Mk3475,
Q2w,
Gestapuran,
NC410,
NP137,
PC14586,
Arm1,
Beam,
Gemcis,
Hydroxydaunomycin,
Ly3537982,
Parpi,
Pcd,
Arm2,
D5w,
Docetaxol,
Evidence,
Skb264,
Depoprovera,
Sominex
Pfizer
Medroxyprogesterone,
Medroxyprogesterone acetate,
Ado-trastuzumab emtansine,
Giredestrant,
Tiragolumab,
Ipatasertib,
Sasanlimab,
Terfenadine,
Bevifimod,
Gedatolisib,
Ag013736
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use